-+ 0.00%
-+ 0.00%
-+ 0.00%

Immutep Showcases Advancements in LAG-3 Immunotherapy and Phase III NSCLC Trial in New Corporate Presentation

Reuters·10/29/2025 06:49:01

Please log in to view news